TY  - JOUR
A1  - Schäfer, Simon
A1  - Weibel, Stephanie
A1  - Donat, Ulrike
A1  - Zhang, Quian
A1  - Aguilar, Richard J.
A1  - Chen, Nanhai G.
A1  - Szalay, Aladar A.
T1  - Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
JF  - BMC Cancer
N2  - Background
Oncolytic viruses, including vaccinia virus (VACV), are a promising alternative to classical mono-cancer treatment methods such as surgery, chemo- or radiotherapy. However, combined therapeutic modalities may be more effective than mono-therapies. In this study, we enhanced the effectiveness of oncolytic virotherapy by matrix metalloproteinase (MMP-9)-mediated degradation of proteins of the tumoral extracellular matrix (ECM), leading to increased viral distribution within the tumors.

Methods
For this study, the oncolytic vaccinia virus GLV-1h255, containing the mmp-9 gene, was constructed and used to treat PC-3 tumor-bearing mice, achieving an intra-tumoral over-expression of MMP-9. The intra-tumoral MMP-9 content was quantified by immunohistochemistry in tumor sections. Therapeutic efficacy of GLV-1h255 was evaluated by monitoring tumor growth kinetics and intra-tumoral virus titers. Microenvironmental changes mediated by the intra-tumoral MMP-9 over-expression were investigated by microscopic quantification of the collagen IV content, the blood vessel density (BVD) and the analysis of lymph node metastasis formation.

Results
GLV-1h255-treatment of PC-3 tumors led to a significant over-expression of intra-tumoral MMP-9, accompanied by a marked decrease in collagen IV content in infected tumor areas, when compared to GLV-1h68-infected tumor areas. This led to considerably elevated virus titers in GLV-1h255 infected tumors, and to enhanced tumor regression. The analysis of the BVD, as well as the lumbar and renal lymph node volumes, revealed lower BVD and significantly smaller lymph nodes in both GLV-1h68- and GLV-1h255- injected mice compared to those injected with PBS, indicating that MMP-9 over-expression does not alter the metastasis-reducing effect of oncolytic VACV.

Conclusions
Taken together, these results indicate that a GLV-1h255-mediated intra-tumoral over-expression of MMP-9 leads to a degradation of collagen IV, facilitating intra-tumoral viral dissemination, and resulting in accelerated tumor regression. We propose that approaches which enhance the oncolytic effect by increasing the intra-tumoral viral load, may be an effective way to improve therapeutic outcome.
KW  - microenvironment
KW  - angiogenesis
KW  - therapy
KW  - cancer
KW  - breast-tumors
KW  - matrix metalloproteinases
KW  - adenovirus
KW  - carcinoma
KW  - prostate
KW  - mice
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-140800
VL  - 12
IS  - 366
ER  - 
TY  - JOUR
A1  - Ascierto, Maria Libera
A1  - Worschech, Andrea
A1  - Yu, Zhiya
A1  - Adams, Sharon
A1  - Reinboth, Jennifer
A1  - Chen, Nanhai G
A1  - Pos, Zoltan
A1  - Roychoudhuri, Rahul
A1  - Di Pasquale, Giovanni
A1  - Bedognetti, Davide
A1  - Uccellini, Lorenzo
A1  - Rossano, Fabio
A1  - Ascierto, Paolo A
A1  - Stroncek, David F
A1  - Restifo, Nicholas P
A1  - Wang, Ena
A1  - Szalay, Aladar A
A1  - Marincola, Francesco M
T1  - Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
JF  - BMC Cancer
N2  - Background: 

Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo. 

Methods: 

In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection. 

Results: 

We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection. 

Conclusions: 

Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.
KW  - gene-therapy
KW  - adenovirus
KW  - receptor
KW  - identification
KW  - infection
KW  - CD9
KW  - panel
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141503
VL  - 11
IS  - 451
ER  -